Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Wednesday, April 23, 2025

View Back issues

Pharma Class Action

Arrowhead Pharmaceuticals stock dropped from $9.36 to $1.44 after the failure of its three proposed drugs for liver disease, shareholders claim in a federal class action.

LOS ANGELES – Arrowhead Pharmaceuticals stock dropped from $9.36 to $1.44 after the failure of its three proposed drugs for liver disease, shareholders claim in a federal class action.

Categories / Business, Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.

Loading...